p95HER2–T cell bispecific antibody for breast cancer treatment

DOI Web Site 1 Citations
  • Irene Rius Ruiz
    Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
  • Rocio Vicario
    Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
  • Beatriz Morancho
    Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
  • Cristina Bernadó Morales
    Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
  • Enrique J. Arenas
    Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
  • Sylvia Herter
    Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Wagistrasse 18, 8952 Schlieren, Switzerland.
  • Anne Freimoser-Grundschober
    Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Wagistrasse 18, 8952 Schlieren, Switzerland.
  • Jitka Somandin
    Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Wagistrasse 18, 8952 Schlieren, Switzerland.
  • Johannes Sam
    Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Wagistrasse 18, 8952 Schlieren, Switzerland.
  • Oliver Ast
    Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Wagistrasse 18, 8952 Schlieren, Switzerland.
  • Águeda Martinez Barriocanal
    Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
  • Antonio Luque
    Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
  • Marta Escorihuela
    Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
  • Ismael Varela
    Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
  • Isabel Cuartas
    Translational Research Program, VHIO, 08035 Barcelona, Spain.
  • Paolo Nuciforo
    Clinical Research Program, VHIO, 08035 Barcelona, Spain.
  • Roberta Fasani
    Clinical Research Program, VHIO, 08035 Barcelona, Spain.
  • Vicente Peg
    Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 08035 Barcelona, Spain.
  • Isabel Rubio
    Vall d’Hebron University Hospital, 08035 Barcelona, Spain.
  • Javier Cortés
    Clinical Research Program, VHIO, 08035 Barcelona, Spain.
  • Violeta Serra
    Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
  • Santiago Escriva-de-Romani
    Clinical Research Program, VHIO, 08035 Barcelona, Spain.
  • Jeff Sperinde
    Monogram Biosciences, Laboratory Corporation of America Holdings, South San Francisco, CA 94080, USA.
  • Ahmed Chenna
    Monogram Biosciences, Laboratory Corporation of America Holdings, South San Francisco, CA 94080, USA.
  • Weidong Huang
    Monogram Biosciences, Laboratory Corporation of America Holdings, South San Francisco, CA 94080, USA.
  • John Winslow
    Monogram Biosciences, Laboratory Corporation of America Holdings, South San Francisco, CA 94080, USA.
  • Joan Albanell
    Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 08035 Barcelona, Spain.
  • Joan Seoane
    Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 08035 Barcelona, Spain.
  • Maurizio Scaltriti
    Department of Pathology, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Jose Baselga
    Department of Medicine, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Josep Tabernero
    Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 08035 Barcelona, Spain.
  • Pablo Umana
    Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Wagistrasse 18, 8952 Schlieren, Switzerland.
  • Marina Bacac
    Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Wagistrasse 18, 8952 Schlieren, Switzerland.
  • Cristina Saura
    Clinical Research Program, VHIO, 08035 Barcelona, Spain.
  • Christian Klein
    Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Wagistrasse 18, 8952 Schlieren, Switzerland.
  • Joaquín Arribas
    Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.

Abstract

<jats:p>T cell bispecific antibodies against an isoform of HER2 effectively target many HER2-expressing tumors but not normal tissues.</jats:p>

Journal

Citations (1)*help

See more

Details 詳細情報について

Report a problem

Back to top